Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Remote Follow-Up of ICD Patients Deemed Safe

By HospiMedica International staff writers
Posted on 20 Oct 2011
Results of a new trial demonstrate the potential safety and efficacy benefits of the remote follow-up of patients with implantable cardioverter defibrillators (ICDs)

Researchers at the University Hospital of Rennes (France) and other institutions reported the results of the EVAluation of TELe follow-up (EVATEL) study, involving 1,501 patients (mean age of 59 years, 85% male) enrolled between January 2008 and January 2010 at 30 centers across France. More...
All participants were followed every three months for an overall period of one year, with half the patient received conventional follow-up at the implant Center, while the other half was followed remotely. The primary end-point of the trial was a clinical composite of death (all causes), cardiovascular hospitalization, and ineffective or inappropriate therapy delivered by the device.

The results showed that the primary endpoint was validated in 28.5% of the control group and 30.2% of the remote group, thus indicating no difference in outcome between the groups. In addition, there were no statistically significant differences between the two groups in time to occurrence of the first primary endpoint and the one-year survival rate. The number of inappropriate therapies was lower in the remote group (4.7%) as compared to the control group (7.5%). The study was presented at the European Society of Cardiology (ESC) annual congress, held during August 2011 in Paris (France).

“The remote follow-up of patients implanted with an ICD seems to be a safe alternative to conventional in-office follow-up,” said lead author and study presenter Philippe Mabo, MD. “However, for the widespread uptake of this new strategy - at least in France - reimbursement from the healthcare system will be needed. We hope that it will be available soon in France.”

A limitation of the study was that 55 patients from the remote-monitoring group eventually crossed over to the control group, while only one patient crossed over from the control group to the remote-monitoring group. In almost all of cases, the switch to the control group was triggered by unexpected problems with the remote transmission system, or the patients' inability to use it. In only two cases did a patient in the remote-monitoring group need to switch to the control group due to their medical condition. As a result, the noninferiority of remote monitoring was demonstrated in the intention-to-treat analysis, but not in the per-protocol analysis.

Related Links:

University Hospital of Rennes




Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.